Summary: Genmab reports financial results for the 12 months ended December 31,
2007.
Copenhagen, Denmark; March 31, 2008 - Genmab A/S (OMX: GEN) announced today
results for the financial year ended December 31, 2007.
Revenues of DKK 530 million (approximately USD 104 million) compared to DKK 136
million (approximately USD 27 million) in 2006.
An Operating Loss of DKK 437 million (approximately USD 86 million). This
compares to an Operating Loss of DKK 472 million (approximately USD 93 million)
reported in 2006.
Net Financial Income totaled DKK 54 million (approximately USD 11 million)
compared to Net Financial Income of DKK 34 million (approximately USD 7 million)
in 2006.
A Net Loss of DKK 383 million (approximately USD 76 million) compared to a Net
Loss in 2006 of DKK 438 million (approximately USD 86 million). The Net Loss
per share was DKK 8.72 (approximately USD 1.72) in 2007 compared to a Net Loss
per share of DKK 11.26 (approximately USD 2.22) in 2006. The 2007 Net Loss
exceeded Genmab's guidance of DKK 260 to 310 million as a development milestone
payment projected for late 2007 was not received until January 2008. The
milestone payment of DKK 87 million was triggered by the first patient receiving
treatment in the HuMax-CD20 (ofatumumab) Phase III rheumatoid arthritis (RA)
program.
Genmab ended the year with a cash position of DKK 3.7 billion (approximately USD
728 million), which is an increase of approximately DKK 2.0 billion
(approximately USD 388 million) from the end of 2006.
USD 1.00 = DKK 5.075 (Danish Central Bank's spot rate on December 31, 2007)
2007 Highlights
Genmab achieved a number of business and scientific milestones, as follows:
Partnership progress
Genmab and GlaxoSmithKline received antitrust clearance for the HuMax-CD20
co-development and commercialization agreement; achieved first two milestones in
collaboration
Achieved three milestones in Roche collaboration
Gained rights to HuMax-CD4 and HuMax-TAC from Merck Serono and HuMax-IL8 through
asset exchange with Medarex
Commenced seven new studies
HuMax-EGFr - Phase III front line head and neck cancer study by DAHANCA and
Phase II non small cell lung cancer study
HuMax-CD20 - Phase II front line CHOP combination study in follicular
non-Hodgkin's lymphoma, 2 RA Phase III studies, Phase II relapsed diffuse large
B-cell lymphoma study
HuMax-CD38 Phase I/II multiple myeloma study
Achieved positive clinical trial results
HuMax-CD20 Phase II RA data
Final HuMax-CD4 Phase II cutaneous T-cell lymphoma (CTCL) data
R1507 Phase I sarcoma data
Presented pre-clinical data
Positive data for HuMax-HepC, HuMax-EGFr and HuMax-CD20
Unique mechanisms of action of HuMax-CD4 and HuMax-EGFr
Financial Highlights
Cash position increased for fourth consecutive year
Achieved membership in OMXC20 index on the OMX Nordic Exchange Copenhagen
2008 Guidance
We expect to significantly expand development in 2008 in our clinical and
pre-clinical programs, including plans to initiate 17 new clinical studies,
filing our first biologics license application and selecting two new clinical
candidates. We will pay development costs for the new and ongoing pivotal
studies in HuMax-CD4 and HuMax-EGFr. Under our collaboration with GSK, we will
fund half the development costs for the trials with HuMax-CD20. We expect to
continue our increasing level of discovery and pre-clinical work in 2008,
developing antibody products for a variety of new and existing disease targets.
Finally, the 2008 projections include operating costs from the newly acquired
antibody manufacturing facility.
Due to these expanded activities, Genmab's operating costs are expected to be
higher in 2008 than in 2007. In combination with increasing revenues in 2008, we
are projecting an operating loss of DKK 900 to 1,000 million compared to the DKK
437 million reported for 2007. Under the conditions described above, the net
loss for 2008 is expected to be in the range of DKK 800 to 900 million compared
to the net loss of DKK 383 million reported for 2007.
As of December 31, 2007, Genmab had cash, cash equivalents and short-term
marketable securities of DKK 3.7 billion (approximately USD 728 million). We
expect the 2008 cash burn to consist of USD 240 million (approximately DKK 1.2
billion) paid for the acquisition of the manufacturing facility, operational
expenses of approximately DKK 750-800 million (approximately USD 148-158
million) and approximately DKK 40-50 million (approximately USD 8-10 million) in
other capital expenditures. We expect to spend over 90% of our 2008 budget on
research and development, including the operation of our manufacturing facility
and less than 10% on general and administrative expenses. Of the research and
development costs, we expect to spend approximately DKK 500 million
(approximately USD 98 million) on development for the ofatumumab program.
Total projected revenues for 2008 are expected to be approximately DKK 1.0
billion (approximately USD 197 million), an increase of approximately DKK 470
million (approximately USD 93 million) over 2007 revenues, which were 530
million (approximately USD 104 million). Net financial income is expected to be
approximately DKK 70-75 million (approximately USD 14-15 million). Thus,
including the manufacturing acquisition and operational expenses, we are
projecting a 2008 year end cash position of DKK 1.7 to 1.8 billion
(approximately USD 335 to 355 million).
The estimates above are subject to possible change primarily due to the timing
and variation of development activities, related income and costs and
fluctuating exchange rates. Our projected 2008 revenues consist primarily of
milestone payments, for which we cannot always predict the exact timing.
Accordingly, any change from projected timing of milestones may directly impact
our estimates. The financial guidance also assumes that no further agreements
are entered into during 2008 that could materially affect the results.
Conversion of our 2008 financial guidance into USD has been made using the
Danish Central bank closing spot rate on December 31, 2007, which was USD 1.00 =
DKK 5.075.
Conference Call
Genmab's management will hold a conference call to discuss the Financial Results
2007, tomorrow, Tuesday April 1, 2008 at:
3:00 pm CEST
2:00 pm BST
9:00 am EDT
The dial in numbers are as follows:
+1 877 741 4253 (in the US) and ask for the Genmab conference call
+1 719 325 4773 (outside the US) and ask for the Genmab conference call
To listen to a live webcast of the call please visit www.genmab.com.
The annual report for 2007 and slides relevant for the conference call can be
found on Genmab's website www.genmab.com. The conference call will be held in
English.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for unmet medical needs. Using cutting-edge
antibody technology, Genmab's world class discovery, development and
manufacturing teams have created and developed an extensive pipeline of products
for potential treatment of a variety of diseases including cancer and autoimmune
disorders. As Genmab advances towards a commercial future, we remain committed
to our primary goal of improving the lives of patients who are in urgent need of
new treatment options. For more information on Genmab's products and
technology, visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab is
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to
actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Stock Exchange Release no. 11/2008
###
Attachments
Recommended Reading
-
Company Announcement COPENHAGEN, Denmark; January 29, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants...
Read More -
Company Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)...
Read More